ERN1 and acute lymphoblastic leukemia: Our recently published findings demonstrate that high risk subsets of acute lymphoblastic leukemia are vulnerable to IRE1α based therapy and that genetic and pharmacological inhibition of IRE1α negatively affects the survival of ALL cells [14, 15].